On last month’s episode of our monthly science talk show GEN Live—“Is Gene Therapy Nearing a Tipping Point?”—I was joined by a pair of gene therapy experts to discuss the state of gene therapy, the promises and pitfalls of delivery vectors, the challenge posed by the immune response, and the safety issues that need to be addressed going forward.
Allison Keeler, PhD, assistant professor at the University of Massachusetts Chan Medical School and the Gene Therapy Center at UMass, studies the immune responses to AAV gene therapy as well as developing novel immunotherapies by cell editing and engineering.